Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00079911 · ClinicalTrials.gov registry record · Phase 4
A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons
A Phase 4 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT00079911 is a Phase 4 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 7 participants.
The verdict
NCT00079911, a Phase 4 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
This clinical research study will be an international trial evaluating the safety and effectiveness of a marketed drug compared to placebo (like a sugar pill) for the suppression of repeated genital herpes infections in HIV-infected subjects with CD4+ count \<100 cells/mm3.
Interventions
- DRUG valacyclovir hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2004-03-12 |
| Est. Completion | 2004-10-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00079911
The ClinicalTrials.gov registry entry for NCT00079911 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which valacyclovir hydrochloride is the first listed.
NCT00079911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00079911 about?
NCT00079911 is a clinical study titled "A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons". This clinical research study will be an international trial evaluating the safety and effectiveness of a marketed drug compared to placebo (like a sugar pill) for the suppression of repeated genital herpes infections in HIV-infected subjects with CD4+ count \<100 cells/mm3.
What is the current status of trial NCT00079911?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2004-03-12. Estimated completion is 2004-10-15.
What interventions are being tested in trial NCT00079911?
The interventions under investigation include: valacyclovir hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00079911?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.